Wealthcare Advisory Partners LLC Purchases 10,839 Shares of Novo Nordisk A/S (NYSE:NVO)

Wealthcare Advisory Partners LLC raised its position in shares of Novo Nordisk A/S (NYSE:NVO) by 74.3% during the 4th quarter, Holdings Channel reports. The fund owned 25,425 shares of the company’s stock after purchasing an additional 10,839 shares during the period. Wealthcare Advisory Partners LLC’s holdings in Novo Nordisk A/S were worth $2,187,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Decker Retirement Planning Inc. purchased a new position in shares of Novo Nordisk A/S in the 4th quarter worth $51,000. Werlinich Asset Management LLC bought a new position in shares of Novo Nordisk A/S in the 4th quarter valued at about $1,055,000. Ritholtz Wealth Management increased its stake in Novo Nordisk A/S by 2.0% during the fourth quarter. Ritholtz Wealth Management now owns 120,826 shares of the company’s stock worth $10,393,000 after acquiring an additional 2,341 shares during the last quarter. Hennion & Walsh Asset Management Inc. raised its position in Novo Nordisk A/S by 9.4% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 19,742 shares of the company’s stock valued at $1,698,000 after purchasing an additional 1,701 shares during the period. Finally, StrongBox Wealth LLC bought a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at approximately $282,000. 11.54% of the stock is currently owned by institutional investors.

Novo Nordisk A/S Trading Down 5.2 %

Shares of NVO opened at $78.74 on Friday. The firm has a market capitalization of $353.33 billion, a price-to-earnings ratio of 25.48, a PEG ratio of 0.92 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 1-year low of $78.17 and a 1-year high of $148.15. The company has a 50-day moving average of $98.33 and a 200 day moving average of $117.69.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BMO Capital Markets reduced their target price on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. Sanford C. Bernstein raised shares of Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research note on Monday, January 6th. UBS Group raised shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research report on Wednesday, January 8th. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. One research analyst has rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.